J&J Plans €1.75B Offer For Dutch Vaccine Developer

Law360, New York (September 20, 2010, 11:42 AM EDT) -- Johnson & Johnson is in advanced talks to buy the bulk of vaccine developer Crucell NV for €1.75 billion ($2.29 billion) through an all-cash public offer that would give the U.S. pharmaceutical giant full control over the Dutch company.

The potential deal, announced Friday, calls for J&J or a subsidiary to purchase all the Crucell shares it does not already own for €24.75 each. The company already owns about 17.9 percent of the Dutch company, valued at about €2.3 billion under the deal.

The negotiations, which...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.